Form 4: Gilead Sciences Director Acquires Stock and Options

Gilead Sciences Director Jacqueline K. Barton acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Summary

• Jacqueline K. Barton, a Director at Gilead Sciences, Inc., acquired 1,146 restricted stock units (RSUs) and a non-qualified stock option for 4,884 shares.
• The RSUs vested immediately upon the grant date of April 30, 2026, and each RSU represents the right to receive one share of common stock.
• The stock option also vested 100% immediately on April 30, 2026, with an exercise price of $130.84 per share.
• Following these transactions, Barton beneficially owns 27,202 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine equity grants to a director rather than significant financial performance or strategic shifts.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• Immediate vesting of RSUs and stock options indicates a reward for past performance or a commitment to future service.
• The acquisition of 1,146 RSUs and 4,884 stock options represents a significant grant to a key executive.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transactions reflect equity grants and vesting.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as RSUs and stock options, to directors and executives is a common practice in the biopharmaceutical industry to align executive interests with shareholder value and to attract and retain talent.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director can be seen as a positive signal of commitment, but the direct financial impact is limited to the value of the granted shares and options.

Key Dates

Keywords

Gilead Sciences, GILD, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Incentive Plan, Director Compensation